COMMUNIQUÉS West-GlobeNewswire

Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation
12/08/2025
Strategic partnership and planned acquisition position Fifty1 Labs to dominate AI-driven drug repurposing and wellness therapeutics at scale VANCOUVER, British Columbia and PALO ALTO, Calif., Aug. 12, 2025 (GLOBE [...]
AVITA Medical Successfully Completes Australian Equity Raise
12/08/2025
Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX) Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$ [...]
Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025
12/08/2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening [...]
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
12/08/2025
New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd [...]
NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
12/08/2025
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12/08/2025
Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th
12/08/2025
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an [...]
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
12/08/2025
Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic [...]
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient [...]
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-driven cancer types; company strengthened financial position and maintains progress toward clinical trials GRAND CAYMAN [...]
SimpleTherapy Ranks No. 1234 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
12/08/2025
Debuts at No. 3 among Fresno-based companies and No. 127 in Healthcare & Medical FRESNO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SimpleTherapy, a leading omnichannel care provider of musculoskeletal (MSK) and [...]
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
12/08/2025
At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) [...]
Counslr Launches in Schools Across the Country to Increase Mental Health Care Access
12/08/2025
Need For Alternative Models Grows in School Communities as Budget Cuts Reduce Student Mental Health Support NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Counslr , a leading mental health and wellness platform , announced [...]
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
12/08/2025
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by [...]
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
12/08/2025
Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd [...]
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
12/08/2025
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 [...]
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
12/08/2025
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for [...]
electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga
12/08/2025
ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice [...]
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
12/08/2025
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain after discontinuation [...]

Pages